HomeCompareSEEL vs JEPI

SEEL vs JEPI: Dividend Comparison 2026

SEEL yields 540.54% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SEEL wins by $112786.20M in total portfolio value
10 years
SEEL
SEEL
● Live price
540.54%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112786.22M
Annual income
$82,692,515,806.61
Full SEEL calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — SEEL vs JEPI

📍 SEEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEELJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEEL + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEEL pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEEL
Annual income on $10K today (after 15% tax)
$45,945.95/yr
After 10yr DRIP, annual income (after tax)
$70,288,638,435.62/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, SEEL beats the other by $70,288,637,136.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEEL + JEPI for your $10,000?

SEEL: 50%JEPI: 50%
100% JEPI50/50100% SEEL
Portfolio after 10yr
$56393.13M
Annual income
$41,346,258,667.62/yr
Blended yield
73.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SEEL right now

SEEL
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-156.6
Piotroski
5/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEEL buys
0
JEPI buys
0
No recent congressional trades found for SEEL or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEELJEPI
Forward yield540.54%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$112786.22M$29.0K
Annual income after 10y$82,692,515,806.61$1,528.62
Total dividends collected$110217.05M$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: SEEL vs JEPI ($10,000, DRIP)

YearSEEL PortfolioSEEL Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$64,754$54,054.05$11,260$840.19+$53.5KSEEL
2$396,410$327,123.28$12,641$907.94+$383.8KSEEL
3$2,295,726$1,871,567.31$14,150$978.20+$2.28MSEEL
4$12,586,137$10,129,710.14$15,795$1,050.85+$12.57MSEEL
5$65,369,349$51,902,182.37$17,584$1,125.74+$65.35MSEEL
6$321,877,325$251,932,121.38$19,526$1,202.74+$321.86MSEEL
7$1,503,762,535$1,159,353,797.14$21,628$1,281.69+$1503.74MSEEL
8$6,671,013,644$5,061,987,731.83$23,898$1,362.43+$6670.99MSEEL
9$28,124,961,234$20,986,976,635.20$26,347$1,444.79+$28124.93MSEEL
10$112,786,224,327$82,692,515,806.61$28,982$1,528.62+$112786.20MSEEL

SEEL vs JEPI: Complete Analysis 2026

SEELStock

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full SEEL Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this SEEL vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEEL vs SCHDSEEL vs OSEEL vs KOSEEL vs MAINSEEL vs JEPQSEEL vs XYLDSEEL vs DIVOSEEL vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.